Details for Patent: 9,314,464
✉ Email this page to a colleague
Which drugs does patent 9,314,464 protect, and when does it expire?
Patent 9,314,464 protects BRAFTOVI and MEKTOVI and is included in two NDAs.
This patent has seventy-seven patent family members in forty-nine countries.
Summary for Patent: 9,314,464
| Title: | Compounds and compositions as protein kinase inhibitors |
| Abstract: | The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. |
| Inventor(s): | Huang; Shenlin (San Diego, CA), Jin; Xianming (San Ramon, CA), Liu; Zuosheng (San Diego, CA), Poon; Daniel (Piedmont, CA), Tellew; John (La Jolla, CA), Wan; Yongqin (Irvine, CA), Wang; Xing (San Diego, CA), Xie; Yongping (San Diego, CA) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 13/931,111 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,314,464
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE | ⤷ Sign Up | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE | ⤷ Sign Up | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,314,464
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2470526 | ⤷ Sign Up | PA2019005 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2727918 | ⤷ Sign Up | PA2019006 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2470526 | ⤷ Sign Up | 300973 | Netherlands | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
